English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Current therapy for Alzheimer's disease (AD) focuses on delaying progression, illustrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates tubulin acetylation and has been implicated as an attractive target. HDAC6 is also elevated in postmortem tissue samples from patients. However, HDAC6 inhibitors have had limited success preclinically due to low blood‐brain barrier penetration.    Method  We investigated a specific, potent HDAC6 inhibitor (ACY‐738) in a mouse model of AD. We determined the effects of ACY‐738 treatment on axonal transport, behavior, and pathology in amyloid precursor protein/presenilin 1 mice.    Results  We demonstrated improvements in in vivo axonal transport in two treatment groups as a result of ACY‐738 brain levels. We also demonstrated recovery of short‐term learning and memory deficits, hyperactivity, and modifications of tau and tubulin.    Discussion  Our findings implicate specific, targeted HDAC6 inhibitors as potential therapeutics and demonstrate that further investigations are warranted into effects of HDAC6 inhibitors in AD.

alzheimer's and dementia: translational research and clinical interventions

Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY‐738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice